Pss32 Validation and Assessment of Measurement Invariance of the Eyelash Satisfaction Questionnaire (Esq) in Us Cancer Patients

Dang, Julie; Hansen, JE; Burgess, SM

doi:10.1016/s1098-3015(10)75269-4

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GEA is a validated four‐point photonumeric scale used by investigators at each site to assess overall eyelash prominence, as indicated by the physical attributes of eyelash length, darkness and thickness (1 = minimal, 2 = moderate, 3 = marked, 4 = very marked). The ESQ is a validated 23‐item patient‐reported outcome questionnaire that measures satisfaction in three domains: physical attributes of length, fullness and overall satisfaction (Domain 1); subjective attributes of confidence, attractiveness and professionalism (Domain 2); and impact on daily routine (Domain 3) . Reponses to questions in ESQ Domain 2 were rated on a five‐point Likert‐type scale (1 = very much disagree; 2 = disagree; 3 = neutral; 4 = agree; 5 = very much agree), with higher scores indicating a higher degree of patient‐reported satisfaction with the subjective attributes of the eyelashes.…”

Section: Methodsmentioning

confidence: 99%

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

et al. 2015

View full text Add to dashboard Cite

SummaryBackgroundBimatoprost ophthalmic solution 0·03% is approved in several countries for the treatment of eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis.ObjectivesTo evaluate the long‐term safety and efficacy of bimatoprost in patients with idiopathic or chemotherapy‐induced hypotrichosis.MethodsThis multicentre, double‐masked, randomized, parallel‐group study included two 6‐month treatment periods [treatment period 1 (TP1) and treatment period 2 (TP2)]. Patients with idiopathic hypotrichosis were randomized to three treatment groups: (i) bimatoprost (TP1 and TP2); (ii) bimatoprost (TP1) and vehicle (TP2); and (iii) vehicle (TP1) and bimatoprost (TP2). Patients with chemotherapy‐induced hypotrichosis were randomized to two treatment groups: (i) bimatoprost or vehicle (TP1) and (ii) bimatoprost (TP2). Primary end point was a composite of at least a one‐grade improvement in investigator‐assessed Global Eyelash Assessment and at least a three‐point improvement in patient‐reported Eyelash Satisfaction Questionnaire Domain 2 at month 4. Secondary measures included digitally assessed eyelash characteristics.ResultsThe primary efficacy end point was met in both populations (idiopathic responder rate was 40·2% for bimatoprost vs. 6·8% for vehicle; postchemotherapy responder rate was 37·5% for bimatoprost vs. 18·2% for vehicle). Efficacy by month 6 was maintained (idiopathic) or enhanced (postchemotherapy) at 12 months. Treatment effects were maintained for approximately 2 months but markedly diminished 4–6 months following treatment cessation in patients with idiopathic hypotrichosis. No drug‐related serious adverse events were reported.ConclusionsDaily treatment with bimatoprost ophthalmic solution 0·03% for 1 year was effective and well tolerated in patients with idiopathic and chemotherapy‐induced hypotrichosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, the Eyelash Satisfaction Questionnaire (ESQ) was validated in a cohort of 595 cancer patients, and it includes 23 questions in 3 domains. 144,145 Management Key point…”

Section: Specific Quality Of Life Instrumentsmentioning

confidence: 99%

Hair disorders in patients with cancer

Freites-Martínez

Shapiro

Goldfarb

et al. 2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders (including alopecia, hirsutism, hypertrichosis, pigmentary and textural hair changes). The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy -induced alopecia has been well-documented mainly in the oncology literature, however the effect of other alterations such as radiation-induced alopecia, hirsutism, changes in hair color or texture on quality of life have not been described. This article reviews clinically significant therapy-related hair disorders in cancer patients, underlying pathophysiological mechanisms, severity grading scales, patient reported quality of life instruments, management strategies, and future translational research opportunities.

show abstract

Pss32 Validation and Assessment of Measurement Invariance of the Eyelash Satisfaction Questionnaire (Esq) in Us Cancer Patients

Cited by 2 publications

References 0 publications

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

Hair disorders in patients with cancer

Contact Info

Product

Resources

About